Iranian journal of kidney diseases最新文献_第4页

Attenuating Renal Interstitial Fibrosis by Shenqi Pill via Reducing Inflammation Response Regulated by NF-κB Pathway In Vitro and In Vivo. 神气丸通过降低体外和体内 NF-κB 通路调控的炎症反应减轻肾间质纤维化

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/kv5ap920

Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng

引用次数: 0

Risk Factors and Clinical Characterization of Cardiovascularand Cerebrovascular Events in Elderly Hemodialysis Patients. 老年血液透析患者心脑血管事件的风险因素和临床特征。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/r2vqgm28

Wei Liu, Hong Ze Wang, Ying Shi, Weiqiang Shen, Mingyan Dai

引用次数: 0

Conceptual Approach to Body Fluids and Edema, Education Determines Clinical Outcomes in Heart Failure. 体液和水肿的概念方法，教育决定心力衰竭的临床结果。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/1aytkx77

Mohammad A Shafiee, Amireza Goli, Pouyan Shaker, Vishal Sharma, Yasmin Shahideh, Khrystyna Maryniak, Behrooz Broumand

引用次数: 0

Microvesicles from Mesenchymal Stem Cells Overexpressing MiR-34a Ameliorate Renal Fibrosis In Vivo. 过表达 MiR-34a 的间充质干细胞微囊可改善体内肾脏纤维化

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/s9bdqs74

Yan Wang, Ping Hu, Yangping Li, Ruijuan Dong, Juan He

{"title":"Microvesicles from Mesenchymal Stem Cells Overexpressing MiR-34a Ameliorate Renal Fibrosis In Vivo.","authors":"Yan Wang, Ping Hu, Yangping Li, Ruijuan Dong, Juan He","doi":"10.5254/s9bdqs74","DOIUrl":"https://doi.org/10.5254/s9bdqs74","url":null,"abstract":"We recently discovered that microvesicles (MVs) derived from mesenchymal stem cells (MSCs) overexpressing miRNA-34a can alleviate experimental kidney injury in mice. In this study, we further explored the effects of miR34a-MV on renal fibrosis in the unilateral ureteral obstruction (UUO) models. Methods. Bone marrow MSCs were modified by lentiviruses overexpressing miR-34a, and MVs were collected from the supernatants of MSCs. C57BL6/J mice were divided into control, unilateral ureteral obstruction (UUO), UUO + MV, UUO + miR-34aMV and UUO + miR-34a-inhibitor-MV groups. MVs were injected to mice after surgery. The mice were then euthanized on day 7 and 14 of modeling, and renal tissues were collected for further analyses by Hematoxylin and eosin, Masson's trichrome, and Immunohistochemical (IHC) staining. Results. The UUO + MV group exhibited a significantly reduced degree of renal interstitial fibrosis with inflammatory cell infiltration, tubular epithelial cell atrophy, and vacuole degeneration compared with the UUO group. Surprisingly, overexpressing miR-34a enhanced these effects of MSC-MV on the UUO mice. Conclusion. Our study demonstrates that miR34a further enhances the effects of MSC-MV on renal fibrosis in mice through the regulation of epithelial-to-mesenchymal transition (EMT) and Notch pathway. miR-34a may be a candidate molecular therapeutic target for the treatment of renal fibrosis. DOI: 10.52547/ijkd.7673.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"9 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140801461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mind the Gap in Kidney Care: Translating What We Know Into What We Do. 关注肾脏护理中的差距：将我们的知识转化为我们的行动。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/sqbbj216

Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci, Or The World Kidney Day Joint Steering Committee

{"title":"Mind the Gap in Kidney Care: Translating What We Know Into What We Do.","authors":"Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci, Or The World Kidney Day Joint Steering Committee","doi":"10.5254/sqbbj216","DOIUrl":"https://doi.org/10.5254/sqbbj216","url":null,"abstract":"Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay. DOI: 10.52547/ijkd.8216.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"50 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140806280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor. PD-1/PD-L1抑制剂治疗的原发性非小细胞肺癌患者发生AKI的风险因素分析

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/0n3xpz60

Jiong-Ming Ying, Feng Yan

引用次数: 0

Correlation Between the 8-hydroxy-2'-deoxyguanosine Level in the Peritoneal Solution of Patients Undergoing Peritoneal Dialysis and the Peritoneal Equilibration Test, Kt/V, Ferritin, and Albumin Levels. 腹膜透析患者腹腔液中 8- 羟基-2'-脱氧鸟苷水平与腹膜平衡试验、Kt/V、铁蛋白和白蛋白水平之间的相关性。

IF 1.3 4区医学

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI: 10.5254/fte08z03

Hadi Khanifar, Leila Mahmoodnia

引用次数: 0

Erratum. 勘误。

IF 0.8 4区医学

Iranian journal of kidney diseases Pub Date : 2024-03-01 DOI: 10.52547/ijkd.8206

Admin Admin

引用次数: 0

Conceptual Approach to Body Fluids and Edema, Education Determines Clinical Outcomes in Heart Failure. 体液和水肿的概念方法，教育决定心力衰竭的临床结果。

IF 0.8 4区医学

Iranian journal of kidney diseases Pub Date : 2024-03-01 DOI: 10.52547/ijkd.8171

Mohammad A Shafiee, Amireza Goli, Pouyan Shaker, Vishal Sharma, Yasmin Shahideh, Khrystyna Maryniak, Behrooz Broumand

引用次数: 0

Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor. PD-1/PD-L1抑制剂治疗的原发性非小细胞肺癌患者发生AKI的风险因素分析

IF 0.8 4区医学

Iranian journal of kidney diseases Pub Date : 2024-03-01 DOI: 10.52547/ijkd.7964

Jiong-Ming Ying, Feng Yan

{"title":"Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor.","authors":"Jiong-Ming Ying, Feng Yan","doi":"10.52547/ijkd.7964","DOIUrl":"https://doi.org/10.52547/ijkd.7964","url":null,"abstract":"Introduction: To investigate the risk factors of Programmed Cell Death Protein 1 (PD-1), Programmed Cell Death Ligand 1(PD-L1) inhibitor associated acute kidney injury (AKI) in patients with primary non-small cell lung cancer (NSCLC) and construct a predictive model.Methods: 120 NSCLC patients were selected as the research subjects and their clinical data were collected. Patients were divided into AKI and Non-AKI (N-AKI) group based on the development of AKI. Exploring the risk factors of PD-1P/D-L1 inhibitor related AKI in NSCLC patients using multivariate logistic regression analysis and visualized the logistic regression analysis to obtain a nomogram model. Meanwhile, evaluate the predictive value of the model.Results: The results of multivariate analysis showed that the presence of extrarenal immune related adverse reactions (irAEs) is a risk factor for PD-1/PD-L1 inhibitor related AKI in NSCLC patients; At the same time, the risk of developing PD-1/PD-L1 inhibitor related AKI in NSCLC patients increases with increasing serum creatinine (SCr) and C-reactive protein (CRP) levels, decreasing baseline estimated glomerular filtration rate (eGFR) levels (P < .05). The analysis results of receiver operator characteristic curve (ROC), calibration curve, and decision curve show that the model has good discrimination and accuracy, and can achieve a high clinical benefit rate.Conclusion: Primary NSCLC patients with extrarenal irAEs, high levels of SCr and CRP, and low levels of eGFR have a higher risk of AKI after PD-1/PD-L1 inhibitor treatment. Establishing a predictive model with high accuracy is more conducive to early detection of high-risk patients. DOI: 10.52547/ijkd.7964.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"18 2","pages":"108-117"},"PeriodicalIF":0.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0